BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Amgen 

Corporate Headquarters
One Amgen Center Drive
Thousand Oaks  California  91320-1789  U.S.A.
Phone: 805-447-1000 Fax: 805-447-1010


SEARCH JOBS




Collaborations

Genesis Research and Development Corporation 

Phylos, Inc.  In 2000, Phylos entered into collaboration with Amgen to apply Phylos' PROfusion™ technology to rapidly identify high-affinity binding agents to potential therapeutic targets supplied by Amgen. Amgen will use the sequences and structural information gained through this collaboration for its internal drug discovery programs.

UCB, Inc.  Contract manufacturing of Abarelix peptide active ingredient

EPIX Pharmaceuticals, Inc. 

Dyax Corp.  Antibody phage display





 Company News
Amgen (AMGN)'s First Quarter 2014 Revenues Increased 7 Percent To $4.5 Billion 4/23/2014 6:41:22 AM    More...
Amgen (AMGN)'s Heart Failure Drug Ivabradine Wins Fast Track Status From The FDA 4/18/2014 8:01:01 AM    More...
Amgen (AMGN) Announces Webcast Of 2014 First Quarter Financial Results 4/18/2014 6:15:52 AM    More...
Amgen (AMGN)'s Melanoma Drug Talimogene Laherparepvec Misses Phase 3 Goals 4/4/2014 7:54:26 AM    More...
Amgen (AMGN) Spends $270 Million To Exit Osteporosis Pact With GlaxoSmithKline (GSK) 4/4/2014 6:10:45 AM    More...
Amgen (AMGN)'s Evolocumab Lowers Cholesterol Up To 66 Percent In Pivotal Phase 3 Studies 3/31/2014 7:16:10 AM    More...
NeuroSigma, Inc. Signs On Two Former Amgen (AMGN) Finance Executives 3/28/2014 6:20:07 AM    More...
Amgen (AMGN) To Webcast Investor Meeting At Upcoming American College of Cardiology's 63rd Annual Scientific Session 3/27/2014 6:35:46 AM    More...
Phase 3 Pivotal Data On Amgen (AMGN)'s Novel Investigational Cholesterol-Lowering Medicine To Be Featured At The American College of Cardiology's 63rd Annual Scientific Session 3/25/2014 6:56:56 AM    More...
Amgen (AMGN) Drug Meets Phase 3 Goals For Those With High Genetic Cholesterol 3/17/2014 8:21:12 AM    More...
12345678910...

//-->